
Topics
Meeting category
Date(s)
11 Sep 2023 - 13 Sep 2023
Location
Rome,
Italy
Meeting type
Hybrid Meeting

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2023
Related Enduring Materials
Enduring Materials
Virtual Program Book Antiviral PK 2023
Virtual Abstract Book Antiviral PK 2023
Day 1 - Monday, 11 September 2023
- 14:00
Opening Lecture: News in Antiviral Pharmacology: A Year in Review
The Use of AI in Clinical Pharmacology
Lauren Walker, MBChB (Hons), PhD, MRCP (UK), PGCAP, FHEA, FBPhS
University of Liverpool, United Kingdom
Session 1: Perspectives on the Role of ARV TDM in Clinical Pharmacology -
Is TDM Still Needed / Useful ?
Session 2: Special Topics in Clinical Pharmacology - Key Populations -
New(er) Antiretrovirals in Pregnancy and Breastfeeding
Pharmacokinetics of Sofosbuvir-Based Direct Acting Antivirals for HCV in Pregnancy
Abstract Oral Presentation #1: Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People with HIV
Mattia Berton
University Hospital Basel, Switzerland
Abstract Oral Presentation #2: Pharmacokinetic Data of Atazanavir/Ritonavir in Second-Line Treatment of Children Living with HIV: Results from the CHAPAS4-trial.
Day 2 - Tuesday, 12 September 2023
Session 3: Next-Generation Therapeutics – Long Acting Drugs -
Knowledge Gaps and Future Perspectives for Treatment Based on Long-Acting Technology
A Year of CAB/RPV Use, What Have We Learned in the Real World
Abstract Oral Presentation #3: Preliminary Results of Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a Large National Cohort of People Living with HIV (ANRS-MIE-CARLA Study).
Caroline Solas Chesneau, PharmD, PhD
University Hospital of La Timone, Aix-Marseille University, France
Session 4: Abstract-Driven Session on Clinical Pharmacology on Pregnancy and HIV -
Abstract Oral Presentation #5: Intracellular Tenofovir-Diphosphate Concentrations with Tenofovir Alafenamide During Pregnancy and Postpartum in People with HIV: Results from IMPAACT 2026
Abstract Oral Presentation #6: Temporal Changes in Dolutegravir and Raltegravir Glucuronide Metabolite to Parent Ratios during Pregnancy and Postpartum
Abstract Oral Presentation #7: Lower Exposure to Bictegravir in Third Trimester in Pregnant Women Living with HIV
Abstract Oral Presentation #8: Prediction of Maternal Pharmacokinetic of Bictegravir in Pregnancy Using Physiologically-Based Pharmacokinetic Modeling
Session 5: Challenges in Managing Complex Drug - Drug Interactions -
Management of Antiplatelet/DOAC DDIS (Pk/PD) - in Context of HIV, HCV, COVID Antiviral Therapy
Short Versus Extended Nirmatrelvir/R Treatment Course and Ensitrelvir: How Do DDIs Differ?
Catia Marzolini, PharmD, PhD
University Hospital of Basel, University Hospital of Lausanne, Switzerland; University of Liverpool, United Kingdom
Case Presentation - Complex DDI case
Case Presentation - Complex DDI case
Session 6: Drug Interactions: PBPK Modelling and Pharmacodynamic Outcomes -
A (PK) Study in Scarlet: Investigating Target Concentrations
Abstract Oral Presentation #9: Physiologically Based Pharmacokinetic Modeling of Lenacapavir Pharmacokinetics and Model Validation with Drug-Drug Interactions Between Lenacapavir with Voriconazole or Rifampicin
Abstract Oral Presentation #10: Dolutegravir But not Bictegravir Exposure Increases in Vitro Platelet Aggregation
Abstract Oral Presentation #11: Genetic Variants Influencing Neuroinflammation Biomarkers in Different Clinical Groups of People Affected by HIV
Session 7: DDI Guidance: Regulatory Landscape and Challenges with Emerging/New Compounds -
Harmonization of DDI Guidelines Among Different Regulatory Agencies: Challenges and Opportunities
A Global Collaboration to Harmonize Guidelines for Clinical Management of Ritonavir-Boosted Nirmatrelvir DDIs
Alice K. Pau, PharmD, FIDSA
National Institute of Allergy and Infectious Disease, National Institutes of Health, United States
Abstract Oral Presentation #12: Nirmatrelvir/Ritonavir Real World Drug-Drug Interaction Management Experience.
Abstract Oral Presentation #13: A Retrospective Descriptive Study of the Management and Consequences of Drug-Drug Interactions between Nirmatrelvir/Ritonavir and Systemic Treatment for Cancer
Abstract Oral Presentation #14: Management of Drug-Drug Interaction and Safety of Oral Anticoagulants with Nirmatrelvir-Ritonavir
Day 3 - Wednesday, 13 September 2023
Session 8: Pharmacologic Data on New and Pipeline Drugs - Industry Session -
Gilead Sciences
GSK - ViiV Healthcare
Shionogi Inc.
Atea Pharmaceuticals, Inc.
Session 9: Abstract-Driven Session on Innovative Tools to Assess Drug Exposure and Adherence -
Abstract Oral Presentation #15: Adherence Blood Sampling Devices Are Not All Created Equal: A Comparative Investigation
Abstract Oral Presentation #16: PrEP at the Site-of-Action in Transgender Women: A Pharmacology Study of Blood and Rectal CD4+ T Lymphocytes
Abstract Oral Presentation #17: Saliva, Tear and Nasal PK of Ritonavir-boosted Nimatrelvir (Paxlovid) in Combination with Molnupiravir in Patients with Laboratory Confirmed COVID-19
Abstract Oral Presentation #18: A Novel Approach to Identify PK Determinants of Efficacy: Implications for HIV-1 Latency Reversal by Romidepsin
Charles Boucher Memorial Session: The Role of Tissue Pharmacology in Response and Cure -
Tissue-Specific Pharmacology: Knowledge and Knowledge Gaps
Tissue-Specific Pharmacology: How Clinically Important Is It
Overview
Registration
Committees
Abstracts
Support
Endorsers
Venue
Media
Previous Editions